Outcome of Board Meeting Dated August 08, 2025 - Financial Results for quarter ended June 30, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Valiant Laboratories reported its audited standalone and consolidated results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations jumped to Rs 5,100.73 lakhs from Rs 1,888.42 lakhs in Q1 FY25, a rise of about 170% year-on-year. The company swung to a standalone net profit of Rs 181.57 lakhs versus a loss of Rs 100.56 lakhs in the same quarter last year. Basic EPS stood at Rs 0.42 versus a loss per share of Rs 0.23 in Q1 FY25. Consolidated net profit was Rs 182.09 lakhs (vs a loss of Rs 50.93 lakhs YoY), with one subsidiary (Valiant Advanced Sciences Pvt Ltd) included in consolidation. The statutory auditor, Raman S. Shah & Co., issued an unqualified audit opinion on both standalone and consolidated results, with no qualifications, emphasis of matter, or going concern flag noted.
Strong year-on-year topline growth and a clear swing back into profitability should be viewed positively by shareholders. With auditor sign-off clean and no exceptional items flagged, the results reinforce operational recovery, though the QoQ dip from Q4 FY25 suggests some sequential moderation worth watching.